Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2006 2
2007 2
2008 2
2009 1
2010 1
2013 1
2014 2
2015 1
2016 4
2017 4
2018 4
2019 3
2020 4
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E, Mai E, Young J, Johnson C, Huseni M, Wang X, Chen Y, Wang P, Wang H, Dybdal N, Chu YW, Chiorazzi N, Scheer JM, Junttila T, Totpal K, Dennis MS, Ebens AJ. Sun LL, et al. Among authors: ellerman d. Sci Transl Med. 2015 May 13;7(287):287ra70. doi: 10.1126/scitranslmed.aaa4802. Sci Transl Med. 2015. PMID: 25972002
Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.
Wang P, Sun LL, Clark R, Hristopoulos M, Chiu CPC, Dillon M, Lin W, Lo AA, Chalsani S, Das Thakur M, Zimmerman Savill KM, Rougé L, Lupardus P, Piskol R, Husain B, Ellerman D, Shivva V, Leong SR, Ovacik M, Totpal K, Wu Y, Spiess C, Lee G, Leipold DD, Polson AG. Wang P, et al. Among authors: ellerman d. Mol Cancer Ther. 2022 Jun 1;21(6):974-985. doi: 10.1158/1535-7163.MCT-21-0599. Mol Cancer Ther. 2022. PMID: 35364611 Free PMC article.
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.
Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, Clark V, Hristopoulos M, Cook R, Slaga D, Nakamura R, McCarty L, Sukumaran S, Luis E, Ye Z, Wu TD, Sumiyoshi T, Danilenko D, Lee GY, Totpal K, Ellerman D, Hötzel I, James JR, Junttila TT. Li J, et al. Among authors: ellerman d. Cancer Cell. 2017 Mar 13;31(3):383-395. doi: 10.1016/j.ccell.2017.02.001. Epub 2017 Mar 2. Cancer Cell. 2017. PMID: 28262555 Free PMC article.
CLEC5a-directed bispecific antibody for effective cellular phagocytosis.
Kedage V, Ellerman D, Fei M, Liang WC, Zhang G, Cheng E, Zhang J, Chen Y, Huang H, Lee WP, Wu Y, Yan M. Kedage V, et al. Among authors: ellerman d. MAbs. 2022 Jan-Dec;14(1):2040083. doi: 10.1080/19420862.2022.2040083. MAbs. 2022. PMID: 35293277 Free PMC article.
Harnessing MerTK agonism for targeted therapeutics.
Kedage V, Ellerman D, Chen Y, Liang WC, Borneo J, Wu Y, Yan M. Kedage V, et al. Among authors: ellerman d. MAbs. 2020 Jan-Dec;12(1):1685832. doi: 10.1080/19420862.2019.1685832. MAbs. 2020. PMID: 31852344 Free PMC article.
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer.
Lo AA, Johnston J, Li J, Mandikian D, Hristopoulos M, Clark R, Nickles D, Liang WC, Hötzel K, Dunlap D, Pham T, Cai H, Ovacik M, Bravo-Perez D, Mai E, Slaga D, Ellerman D, Ziai J, Totpal K, Lee G, Boswell CA, Payandeh J, Wu Y, Junttila TT. Lo AA, et al. Among authors: ellerman d. Mol Cancer Ther. 2021 Apr;20(4):716-725. doi: 10.1158/1535-7163.MCT-20-0490. Epub 2021 Feb 3. Mol Cancer Ther. 2021. PMID: 33536191
32 results